Literature DB >> 21907804

Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection.

Sharif Ali1, Adrian Ormsby, Veena Shah, Maria C Segovia, Kristin L Kantz, Sharon Skorupski, A Bradley Eisenbrey, Meredith Mahan, Mary Ann Y Huang.   

Abstract

Diagnosis of liver allograft antibody-mediated rejection (AMR) is difficult and requires a constellation of clinical, laboratory and histologic features that support the disease and exclude other causes. Histologic features of AMR may intermix with those of biliary obstruction, preservation/reperfusion injury, and graft ischemia. Tissue examination for complement degradation product 4d (C4d) has been proved to support this diagnosis in other allografts. For this reason, we conducted a retrospective review of all ABO compatible/identical re-transplanted liver patients with primary focus on identifying AMR as a possible cause of graft failure and to investigate the utility of C4d in liver allograft specimens. We reviewed 193 liver samples obtained from 53 consecutive ABO-compatible re-transplant patients. 142 specimens were stained with C4d. Anti-donor antibody screening and identification was determined by Luminex100 flow cytometry. For the study analysis, patients were stratified into 3 groups according to time to graft failure: group A, patients with graft failure within 0-7 days (n=7), group B within 8-90 days (n=13) and C >90 days (n=33). Two patients (3.7%) met the diagnostic criteria of acute AMR. Both patients experienced rapid decline of graft function with presence of donor specific antibodies (DSA), morphologic evidence of humoral rejection and C4d deposition in liver specimens. C4d-positive staining was identified in different medical liver conditions i.e., acute cellular rejection (52%), chronic ductopenic rejection (50%), recurrent liver disease (48%), preservation injury (18%), and hepatic necrosis (54%). Univariate analysis showed no significant difference of C4d-positive staining among the 3 patients groups, or patients with DSA (P>.05). In conclusion, AMR after ABO-compatible liver transplantation is an uncommon cause of graft failure. Unlike other solid organ allografts, C4d-positive staining is not a rugged indicator of humoral rejection, thus, interpretation should be done with caution to avoid diagnostic dilemmas.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907804     DOI: 10.1016/j.trim.2011.08.005

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  10 in total

1.  Bortezomib for acute antibody-mediated rejection in liver transplantation.

Authors:  F Paterno; M Shiller; G Tillery; J G O'Leary; B Susskind; J Trotter; G B Klintmalm
Journal:  Am J Transplant       Date:  2012-06-08       Impact factor: 8.086

Review 2.  Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms.

Authors:  Nicole M Valenzuela; Jeffrey T McNamara; Elaine F Reed
Journal:  Curr Opin Organ Transplant       Date:  2014-02       Impact factor: 2.640

Review 3.  Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.

Authors:  Antonio Cuadrado; David San Segundo; Marcos López-Hoyos; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 4.  Liver transplantation: Current status and challenges.

Authors:  Caroline C Jadlowiec; Timucin Taner
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

Review 5.  Long-term outcomes of children after solid organ transplantation.

Authors:  Jon Jin Kim; Stephen D Marks
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

6.  De Novo Donor Specific Antibody and Long-Term Outcome After Liver Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Zahra Beyzaei; Bita Geramizadeh; Zahra Bagheri; Sara Karimzadeh; Alireza Shojazadeh
Journal:  Front Immunol       Date:  2020-12-23       Impact factor: 7.561

7.  Acute liver failure secondary to acute antibody mediated rejection after compatible liver transplant: A case report.

Authors:  Todd J Robinson; James B Hendele; Idoia Gimferrer; Nicolae Leca; Scott W Biggins; Jorge D Reyes; Lena Sibulesky
Journal:  World J Hepatol       Date:  2022-01-27

8.  Acute Antibody-mediated Rejection Coexisting With T Cell-mediated Rejection in Pediatric ABO-incompatible Transplantation.

Authors:  Yusuke Yanagi; Seisuke Sakamoto; Masaki Yamada; Koutaro Mimori; Toshimasa Nakao; Tasuku Kodama; Hajime Uchida; Seiichi Shimizu; Akinari Fukuda; Noriyuki Nakano; Chiduko Haga; Takako Yoshioka; Mureo Kasahara
Journal:  Transplant Direct       Date:  2022-08-04

9.  Biliary epithelial senescence and plasticity in acute cellular rejection.

Authors:  J G Brain; H Robertson; E Thompson; E H Humphreys; A Gardner; T A Booth; D E J Jones; S C Afford; T von Zglinicki; A D Burt; J A Kirby
Journal:  Am J Transplant       Date:  2013-06-10       Impact factor: 8.086

Review 10.  Late and chronic antibody-mediated rejection: main barrier to long term graft survival.

Authors:  Qiquan Sun; Yang Yang
Journal:  Clin Dev Immunol       Date:  2013-10-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.